- Home
- ATNM vs RMCO Comparison
ATNM vs RMCO Comparison
Compare ATNM & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- RMCO
- Stock Information
- Founded
- ATNM 2000
- RMCO 2021
- Country
- ATNM United States
- RMCO United States
- Employees
- ATNM N/A
- RMCO N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- RMCO Multi-Sector Companies
- Sector
- ATNM Health Care
- RMCO Miscellaneous
- Exchange
- ATNM Nasdaq
- RMCO Nasdaq
- Market Cap
- ATNM 50.2M
- RMCO 45.7M
- IPO Year
- ATNM N/A
- RMCO N/A
- Fundamental
- Price
- ATNM $1.51
- RMCO $2.97
- Analyst Decision
- ATNM Strong Buy
- RMCO Buy
- Analyst Count
- ATNM 2
- RMCO 1
- Target Price
- ATNM $4.50
- RMCO N/A
- AVG Volume (30 Days)
- ATNM 160.4K
- RMCO 162.9K
- Earning Date
- ATNM 11-13-2025
- RMCO 11-14-2025
- Dividend Yield
- ATNM N/A
- RMCO 0.33%
- EPS Growth
- ATNM N/A
- RMCO N/A
- EPS
- ATNM N/A
- RMCO N/A
- Revenue
- ATNM N/A
- RMCO $2,641,171.00
- Revenue This Year
- ATNM N/A
- RMCO N/A
- Revenue Next Year
- ATNM N/A
- RMCO N/A
- P/E Ratio
- ATNM N/A
- RMCO N/A
- Revenue Growth
- ATNM N/A
- RMCO 292.46
- 52 Week Low
- ATNM $1.03
- RMCO $0.90
- 52 Week High
- ATNM $2.41
- RMCO $4.76
- Technical
- Relative Strength Index (RSI)
- ATNM 43.91
- RMCO 54.16
- Support Level
- ATNM $1.47
- RMCO $2.84
- Resistance Level
- ATNM $1.59
- RMCO $4.29
- Average True Range (ATR)
- ATNM 0.08
- RMCO 0.53
- MACD
- ATNM -0.00
- RMCO 0.03
- Stochastic Oscillator
- ATNM 28.95
- RMCO 35.59
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.